186 related articles for article (PubMed ID: 15867209)
1. Increased estrogen receptor betacx expression during mammary carcinogenesis.
Esslimani-Sahla M; Kramar A; Simony-Lafontaine J; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2005 May; 11(9):3170-4. PubMed ID: 15867209
[TBL] [Abstract][Full Text] [Related]
2. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
Bozkurt KK; Kapucuoğlu N
Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
[TBL] [Abstract][Full Text] [Related]
4. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
5. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
6. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer.
Sugiura H; Toyama T; Hara Y; Zhang Z; Kobayashi S; Fujii Y; Iwase H; Yamashita H
Jpn J Clin Oncol; 2007 Nov; 37(11):820-8. PubMed ID: 17932113
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.
Savinov AY; Remacle AG; Golubkov VS; Krajewska M; Kennedy S; Duffy MJ; Rozanov DV; Krajewski S; Strongin AY
Cancer Res; 2006 Mar; 66(5):2716-24. PubMed ID: 16510592
[TBL] [Abstract][Full Text] [Related]
10. Impact of AdipoR1 expression on breast cancer development.
Pfeiler G; Hudelist G; Wülfing P; Mattsson B; Königsberg R; Kubista E; Singer CF
Gynecol Oncol; 2010 Apr; 117(1):134-8. PubMed ID: 20071013
[TBL] [Abstract][Full Text] [Related]
11. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
12. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7.
Omoto Y; Eguchi H; Yamamoto-Yamaguchi Y; Hayashi S
Oncogene; 2003 Aug; 22(32):5011-20. PubMed ID: 12902984
[TBL] [Abstract][Full Text] [Related]
14. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
15. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
17. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
18. Minimal breast cancer: evaluation of histology and biological marker expression.
Dublin EA; Millis RR; Smith P; Bobrow LG
Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
[TBL] [Abstract][Full Text] [Related]
19. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer.
Nerlich AG; Wiest I; Wagner E; Sauer U; Schleicher ED
Anticancer Res; 1997; 17(6D):4443-9. PubMed ID: 9494547
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer.
Fujimura T; Takahashi S; Urano T; Ogawa S; Ouchi Y; Kitamura T; Muramatsu M; Inoue S
Biochem Biophys Res Commun; 2001 Dec; 289(3):692-9. PubMed ID: 11726203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
